Advances in treatment of hepatitis delta virus infection: Update on novel investigational drugs

Table 1 Current global society recommendations for hepatitis delta virus treatment

Society	Therapy	Length of therapy
AASLD	Peg-IFN α	12 months
APASL	Peg-IFN α	12-18 months
EASL	Peg-IFN α for 48 weeks (finite therapy)
	Or Bulevirtide 2 mg daily (long term therapy)
	Or Peg-IFN α + Bulevirtide

AASLD: American Association for the Study of Liver Disease; APASL: Asia-Pacific Association for Study of Liver; EASL: European Association for the Study of the Liver; Peg-IFN: Pegylated interferon.

Table 2 Novel therapeutic agents for hepatitis D infection in phase II or III development

Therapeutic class	Therapeutic agents	Drug sponsor	Phase
Entry inhibitors	Bulevirtide	Gilead	III
	HH-003[61]	HuaHei	II
Prenylation inhibitor	Lonafarnib	Eiger InnoTherapeutics	III
Immunomodulators	Peginterferon Lambda	Eiger InnoTherapeutics	II
	Ropeg-IFN α2b (P1101)[62,63]	PharmaEssentia	II
HBsAg target drugs	REP 2139	Replicor	II
RNA interference molecule	JNJ-73753989 (JNJ-3989)	GlaxoSmithKline Pharmaceuticals	II (for HBV)
	Elebsiran (VIR-2218)[54,55]	Vir Biotechnology	II (for HBV, HDV)
	RBD 1016[64]	Ribocure	II
Active site polymerase inhibitor	ATI-2173[65]	Antios	II (terminated)
Monoclonal antibody	BJT-778[60]	Bluejay	II
	Tobevibart (VIR-3434)[54,55]	Vir Biotechnology	II

HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; HDV: Hepatitis delta virus.